TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00886730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Card
Description: Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Centered Brochure
Description: Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician's endorsement
Description: Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
Study: NCT00495703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6-months of regular aerobic exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: 6-months of behavioral strategies to aid memory/cognition
Study: NCT02475421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: One hour glucagon-clamp followed by one hour of blood sampling

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: One hour glucagon-clamp followed by one hour of blood sampling

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: One hour glucagon-clamp followed by one hour of blood sampling

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: One hour glucagon-clamp followed by one hour of blood sampling
Study: NCT03348124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children - what does it involve?
Description: Thirteen educational lessons based on the conversational material Toolkit will be delivered in the classroom at school, two lessons per theme. The themes consists of: 1) a card game: What i wish 2) Time 3) Money 4) Skills 5) Relations 6) Housing. The material is prepared and same for all schools. This intervention will be given 1-2 lessons per week over a period of 8-14 weeks. During this period the students also care for the RCB simulator during three days and nights, but with a break for day care for the simulator which was between 7 am and 5 pm when the students were in school. All students will practice handling the simulator to be familiar with all types of needs: to rock, change diaper, feed and burp and were taught the skills of head support, techniques to avoid rough handling.
Study: NCT03789981

Intervention type: GENETIC
Intervention: Immunogenic profile
Description: RNA sequencing (RNAseq), Whole exome sequencing (WES), NeoAntigens (NeoAg), Immune checkpoints analysis, Gene expression profiling

Intervention type: GENETIC
Intervention: Immunogenic profile
Description: RNA sequencing (RNAseq), Whole exome sequencing (WES), NeoAntigens (NeoAg), Immune checkpoints analysis, Gene expression profiling
Study: NCT00786162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-enabled automated self-management program
Description: An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BP cuff at workplace
Description: Provided BP cuff for communal use at the worksite
Study: NCT03698279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Study: NCT00490802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT03167034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
Study: NCT03507348

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab 375 mg/m2 at Day-15 (only for donors living)
Description: Rituximab 375 mg/m2 at Day-15
Study: NCT03698279

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)
Description: Pharmaceutical form: Solution for injection Route of administration: IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Description: Pharmaceutical form: Solution for injection Route of administration: IM
Study: NCT03507348

Intervention type: OTHER
Group type: OTHER
Intervention: Transplant Day-0
Description: TRANSPLANTATION
Study: NCT03583229

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 75mg
Description: 7 days treatment with 75 mg aspirin daily.
Study: NCT03181698

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: A full Magnetic Resonance Imaging examination of the brain will be done for each of the subjects included in the study. The protocol of the study will include a high-resolution thin-cuts three Dimensions-T1 weighted gradient echo sequence to be used for the morphometric study.~The obtained images will be analyzed for any gross structural abnormalities. by using fully-automated computational voxel-based volumetric software that calculates the volume of different structures of the brain. The obtained data will be analyzed statistically using linear regression tests to determine the differences between Bipolar Disorder type I mania patients and the healthy controls

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: A full Magnetic Resonance Imaging examination of the brain will be done for each of the subjects included in the study. The protocol of the study will include a high-resolution thin-cuts three Dimensions-T1 weighted gradient echo sequence to be used for the morphometric study.~The obtained images will be analyzed for any gross structural abnormalities. by using fully-automated computational voxel-based volumetric software that calculates the volume of different structures of the brain. The obtained data will be analyzed statistically using linear regression tests to determine the differences between Bipolar Disorder type I mania patients and the healthy controls
Study: NCT01164865

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care contact lens care system
Description: FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
Study: NCT03167034

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT03930225

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stigma Directed Psycho-educational Intervention program
Description: psycho-educational intervention with emphasis on Stigma

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Directed Psycho-educational Intervention program
Description: psycho-educational intervention with emphasis on Stigma
Study: NCT01164865

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lenses
Description: Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
Study: NCT02070302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Normal Saline) divided into 2 injections of .4cc each
Study: NCT04254939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS3007 (BLU-285)
Description: A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days.
Study: NCT03358784

Intervention type: PROCEDURE
Intervention: Hemi-shoulder Arthroplasty
Description: Hemi-shoulder Arthroplasty treating three or four-part fractures of proximal humerus

Intervention type: PROCEDURE
Intervention: PHILOS Plate
Description: PHILOS plate treating three or four-part fractures of proximal humerus
Study: NCT03704402

Intervention type: OTHER
Intervention: Alcohol policy
Description: Introduction of new mutual alcohol policy
Study: NCT03532113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Updating
Description: Updating is trained across 12 sessions using N-back-type exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of the stimuli (numbers vs. symbols) is changed halfway in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibition
Description: Inhibition is trained across 12 sessions with Stroop-like exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of stimuli (letters vs. numbers) is changed halfway in each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General knowledge
Description: General Knowledge is trained across 12 sessions. Participants complete four-choice questions relating to general knowledge and vocabulary and are provided with the correct answer and a short explanation. Questions are displayed one by one on a computer screen with a maximum of 20 seconds per question. Each session lasts 30 minutes and includes 2 blocks of 40 new questions each (about 220 seconds per block). Questions with wrong answers are displayed again at the end of each block.
Study: NCT03583229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75mg
Description: 7 days treatment with 75 mg aspirin daily.
Study: NCT03086369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT02297061

Intervention type: BIOLOGICAL
Intervention: Thrombelastography analysis (TEG)
Description: TEG analysis is performed on admission
Study: NCT05049434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medicurtain®
Description: Medicurtain® 5ml prefilled syringe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GUARDIX-SG®
Description: GUARDIX-SG® 5ml prefilled syringe
Study: NCT00683696

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
Description: All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
Description: All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
Study: NCT06281054

Intervention type: PROCEDURE
Intervention: Revascularization
Description: Performing PCI or CABG
Study: NCT03090776

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: low dose bolus and infusion ketamine, administered under general anesthesia

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: low dose bolus and infusion ketamine, administered under general anesthesia

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo saline
Description: bolus and infusion saline, administered under general anesthesia

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo saline
Description: bolus and infusion saline, administered under general anesthesia
Study: NCT01154985

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: 3x Placebo capsules three times a day (TID) for 365 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA-E 300 mg capsule
Description: 2x 300 mg capsules + placebo capsule TID for 365 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA-E 300 mg capsule
Description: 3x 300 mg capsules TID for 365 days
Study: NCT00962234

Intervention type: OTHER
Intervention: Blood draws
Description: Up to 4 blood draws will be required, in the amount of about 10 mL each

Intervention type: BIOLOGICAL
Intervention: Oral administration of stable isotope (deuterium)
Description: 1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours

Intervention type: PROCEDURE
Intervention: Metabolic rate testing
Description: Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
Study: NCT02306954

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High Dose IL-2
Description: High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose IL-2
Description: High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
Study: NCT04339348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal misoprostol
Description: vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus inert placebo cream vaginally at the time of LNG-IUD insertion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-Prilocaine Topical cream
Description: Lidocaine-Prilocaine cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inert placebo cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
Study: NCT01519752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxiconazole Nitrate Cream 1%
Description: Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxiconazole Nitrate Cream 1% (Oxistat®)
Description: Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo applied to affected area once a day for 28 days
Study: NCT00085436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin,
Description: Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous tumor cell vaccine
Description: we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
Study: NCT03090763

Intervention type: GENETIC
Intervention: PCR and sequencing
Description: Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.

Intervention type: GENETIC
Intervention: PCR and sequencing
Description: Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.